منابع مشابه
Neu antigen-negative variants can be generated after neu-specific antibody therapy in neu transgenic mice.
Prolonged administration of HER-2/neu-specific monoclonal antibody therapy is now widely used for the treatment of HER-2/neu-overexpressing tumors in advanced-stage breast cancer patients. Monoclonal antibody therapy has the potential to promote reduced tumor expression of HER-2/neu by receptor down-modulation and/or the generation of antigen-negative variants. Loss of antigen by either mechani...
متن کاملActivating mutations in HER2: neu opportunities and neu challenges.
Twenty-five years after the publication of seminal studies showing that HER2 gene amplification and protein overexpression are oncogenic in breast cancer, Bose and colleagues report on the identification of activating HER2 somatic mutations that, albeit rare, may determine the response of breast cancer cells to anti-HER2 agents. These results herald a new era for the potential use of existing H...
متن کاملSupporting information neu überarbeitet
The reaction was carried out in dry EtOH under an argon atmosphere and at room temperature. NMR spectrum was recorded with a Bruker Avance 300 spectrometer and all chemical shifts are reported relative to the solvent signal [CDCl3: 7.26 ppm ( H)]. The assignments of the NMR signals were carried out under using 2D-NMR experiments H-HCOSY. IR spectra were recorded with a Thermo Nicolet NEXUS FTIR...
متن کاملDetermination of Soluble HER-2/neu (sHER-2/neu) in Iranian Patients with Lung Cancer
Background: The HER-2/neu gene is located on chromosome 17q21 and encodes a 185-kDa transmembrane glycoprotein with tyrosine kinase activity reported to be released in soluble form in various malignancies. Objective: To evaluate the clinical significance of soluble Her-2/neu as a diagnostic marker in lung cancer. Methods: Serum levels of soluble HER-2/neu were measured in 43 patients with lung ...
متن کاملIN THE SPOTLIGHT Activating Mutations in HER2 : Neu Opportunities and Neu Challenges
Authors’ Affi liation: Department of Pathology, Memorial Sloan-Kettering Cancer Center, New York, New York Corresponding Author: Jorge S. Reis-Filho, Department of Pathology, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY 10065. Phone: 212-639-8054; Fax: 212-772-8521; E-mail: reisfi lj@ mskcc.org doi: 10.1158/2159-8290.CD-12-0585 ©2012 American Association for Cancer Res...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: physiopraxis
سال: 2012
ISSN: 1439-023X,1869-5515
DOI: 10.1055/s-0032-1309070